Researchers who used PET with F-18 flortaucipir and C-11 Pittsburgh Compound B found that cognitively normal adults likely to develop Alzheimer's disease due to a presenilin 1 E280A gene mutation had increased beta-amyloid accumulation in their late 20s, about 15 years before expected mild cognitive impairment onset, and also had elevated tau deposits in the medial temporal lobe in their late 30s, compared with those without the gene mutation. The findings in JAMA Neurology suggest tau PET may be effective in identifying people with a high risk of Alzheimer's and tracking Alzheimer's progression, but more studies are needed, researchers said.
Study evaluates tau PET in autosomal-dominant Alzheimer's disease
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.